Early paracentral visual field loss in patients taking hydroxychloroquine

Archives of Ophthalmology

Volumn 124, Issue 12, 2006, Pages 1729-1733

  Elder, Mark ^a,c   Rahman, Anmar M A ^b   McLay, Jan ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b DUNEDIN HOSPITAL   (New Zealand)

^c CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT;

DIARRHEA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HEADACHE; HUMAN; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SCREENING; SYSTEMIC LUPUS ERYTHEMATOSUS; TINNITUS; VISUAL IMPAIRMENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; CHILD; FEMALE; HUMANS; HYDROXYCHLOROQUINE; KIDNEY FUNCTION TESTS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PERIMETRY; RETINA; RETROSPECTIVE STUDIES; VISION DISORDERS; VISUAL FIELDS;

EID: 33845510659     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.124.12.1729     Document Type: Review

References (17)

1. Grant S. Toxic retinopathies. In: Tasman W, Jaeger EA, eds. Duane's Clinical Ophthalmology. Vol 3. Rev ed. Philadelphia, Pa: JB Lippincott-Raven; 1996:1-12.
2. McChesney EW. Animal toxicity and pharmacokinetics of hydroxychloroquine sulphate. Am J Med. 1983;75:11-18.
3. Bernstein HN. Ocular safety of hydroxychloroquine sulfate (Plaquenil). South Med J. 1992;85:274-279.
4. Bishara SA, Matamoros N. Evaluation of several tests in screening for chloroquine maculopathy. Eye. 1989;3:777-782.
5. Finbloom DS, Silver K, Newsome DA, et al. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol. 1985;12:692-694.
6. Falcone PM, Paolini L, Lou PL. Hydroxychloroquine toxicity despite normal dose therapy. Ann Ophthalmol. 1993;25:385-388.
7. Levy GD, Munz SJ, Paschal J, et al. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum. 1997;40:1482-1486.
8. Spalton DJ. Retinopathy and antimalarial drugs - the British experience. Lupus. 1996;5:S70-S72.
9. Jones SK. Ocular toxicity and hydroxychloroquine: guidelines for screening. Br J Dermatol. 1999;140:3-7.
10. Grierson DJ. Hydroxychloroquine and visual screening in a rheumatology outpatient. Ann Rheum Dis. 1997;56:188-190.
11. Morsman CD, Livesey SJ, Richards IM, et al. Screening for hydroxychloroquine retinal toxicity: is it necessary? Eye. 1990;4:572-576.
12. Morand EF, McCloud PI, Littlejohn GO. Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis. 1992;51:1318-1321.
13. Fielder A, Graham E, Jones S, Silman A, Tullo A. Royal College of Ophthalmologists guidelines: ocular toxicity and hydroxychloroquine. Eye. 1998;12:907-909.
14. Bienfang D, Coblyn JS, Liang MH, Corzillius M. Hydroxychloroquine retinopathy despite regular ophthalmic evaluation: a consecutive series. J Rheumatol. 2000;27:2703-2706.
15. Easterbrook M. An ophthalmological view on the efficacy and safety of chloroquine versus hydroxychloroquine. J Rheumatol. 1999;26:1866-1867.
16. Easterbrook M. Ocular effects and safety of antimalarial agents. Am J Med. 1988;85:23-29.
17. Marmor MF, Carr R, Easterbrook M, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology. 2002;109:1377-1382.